Most Cited & Viewed

Most Cited & Viewed Papers

Citations Article
 
Integrative Statistics, Machine Learning and Artificial Intelligence Neural Network Analysis Correlated CSF1R with the Prognosis of Diffuse Large B-Cell Lymphoma
 
Barriers and Facilitators of Use of Hydroxyurea among Children with Sickle Cell Disease: Experiences of Stakeholders in Tanzania
 
SARS-CoV-2 and Autoimmune Cytopenia
 
Why Immunotherapy Fails in Multiple Myeloma
 
Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis
 
CAR-T Cell Therapy for the Treatment of ALL: Eradication Conditions and In Silico Experimentation
 
Persisting Endothelial Cell Activation and Hypercoagulability after COVID-19 Recovery—The Prospective Observational ROADMAP-Post COVID-19 Study
 
Primary Cutaneous B-Cell Lymphoma: An Update on Pathologic and Molecular Features
 
Cold Agglutinin Disease: Improved Understanding of Pathogenesis Helps Define Targets for Therapy
 
Role and Modulation of NK Cells in Multiple Myeloma
Views Article
Why Immunotherapy Fails in Multiple Myeloma
Cold Agglutinin Disease: A Distinct Clonal B-Cell Lymphoproliferative Disorder of the Bone Marrow
Sickle Cell Disease, a Review
Peripheral T-Cell Lymphomas of the T Follicular Helper Type: Clinical, Pathological, and Genetic Attributes
Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis
Classification of Tumors of the Hematopoietic and Lymphoid Tissues. Discovering Diseases—Defining Their Features
Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy
Pathophysiology of Myelodysplastic Syndromes
Future Developments in the Treatment of AL Amyloidosis
Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1
Downloads Article
Classification of Tumors of the Hematopoietic and Lymphoid Tissues. Discovering Diseases—Defining Their Features
Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes
Why Immunotherapy Fails in Multiple Myeloma
Sickle Cell Disease, a Review
The Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study
Impaired Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation: Its Pathogenesis and Potential Treatments
Treatment of Lower Risk Myelodysplastic Syndromes
The Management of Hematologic Patients with Bloodstream Infections Due to Multi-Drug Resistant Bacteria: Where Do We Stand? From Antibacterial Prophylaxis to the Treatment of Septic Shock
Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?
SARS-CoV-2 and Autoimmune Cytopenia
Back to TopTop